港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

抗疫概念

875.916

-12.161-1.37%

漲家數：3

跌家數：13

平家數：1

市盈率：- -

高：893.115

開：887.975

低：873.648

收：888.076

成交量：2.59億

成交額：17.47億

市值：5,923.57億

流通市值：4,901.67億

資料載入中...

總覽新聞資訊

中國中藥(00570.HK)附屬簽訂車間改造項目工程總承包合同及產能提升技術改造項目工程總承包合同

中國中藥旗下子公司簽約山東益方改造項目，合同金額1060萬元及其他事項

阿里健康(00241)授出合共767.25萬個受限制股份單位

董事長兼總裁吳豫生增持同源康醫藥-B(02410.HK)40萬股每股作價約2.82港元

石藥集團(01093)：SYS 6010於中國獲國家藥監局納入突破性治療品種名單用於治療驅動基因陰性非鱗狀非小細胞肺癌患者

復星醫藥：9月15日回購130萬股股份

勁方醫藥-B(02595)9月15日斥資129.56萬港元回購5萬股

復星醫藥(02196.HK)周二回購130萬股涉2,207萬元

阿斯达克财经

前任合作匆匆落幕後，彌可保推廣權易手國藥控股

阿里健康(00241)出現大手買入160萬股，成交價$2.915，涉資466.4萬

阿斯达克财经

王老吉繼續「降温」

鋰電池板塊走弱寧德時代（03750）跌超4% 行業產能過剩壓力凸顯

港股異動 | 禮邦醫藥-B(09637)午後飆升逾17% AP308治療IgA腎病新藥臨床申請獲美國FDA批准

禮邦醫藥－Ｂ(09637)股價顯著上升14.696%，現價港幣$26.38

阿斯达克财经

渠道紅利見頂，主動投研掉隊工銀瑞信的權益短板誰來補？

同源康醫藥－Ｂ(02410)股價大幅上升15.635%，現價港幣$3.55

阿斯达克财经

港股異動 | 同源康醫藥-B(02410)漲逾10% 大股東增持提振市場信心此前核心品種已順利獲批

勁方醫藥-B(02595.HK)：GFH375(口服KRAS G12D抑制劑)II期單藥治療經治NSCLC優效數據登陸2026世界肺癌大會口頭報告

勁方醫藥-B(02595)：GFH375(口服KRAS G12D抑制劑)II期單藥治療經治NSCLC優效數據登陸2026世界肺癌大會口頭報告

董事長兼總裁吳豫生增持同源康醫藥-B(02410)17萬股每股作價約2.7港元

智通财经网

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/BK1515/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"抗疫概念","latestPrice":875.9157,"timestamp":1789459707407,"preClose":888.07635,"halted":0,"volume":258517563,"delay":0,"changeRate":-0.013693,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":-12.160645,"latestTime":"09-15 16:00:00","open":887.9753,"high":893.115,"low":873.64844,"amount":1747446787,"amplitude":0.02192,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789522200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789435800000,1789444800000],[1789448400000,1789459200000]],"pbRate":1.333444,"peRate":17.280209,"turnoverRate":0.003315,"increases":2,"decrements":13,"flats":2,"marketCap":592357498176,"floatMarketCap":490167420608},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":893.115,"amplitude":0.02192,"preClose":888.07635,"low":873.64844,"pbRate":"1.333444","latestPrice":875.9157,"volume":258517563,"delay":0,"open":887.9753,"prevYearClose":1190.107,"prevWeekClose":878.789,"prevMonthClose":925.265,"prevQuarterClose":802.777,"fiveDayClose":942.498,"twentyDayClose":909.79,"sixtyDayClose":823.11,"secType":"PLATE","market":"HK","turnoverRate":0.003315,"peRate":17.280209,"marketCap":592357498176,"floatMarketCap":490167420608,"timestamp":1789459707407,"nameCN":"抗疫概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":3,"down":13,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667642784","title":"中國中藥(00570.HK)附屬簽訂車間改造項目工程總承包合同及產能提升技術改造項目工程總承包合同","url":"https://stock-news.laohu8.com/highlight/detail?id=2667642784","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667642784?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 20:32","pubTimestamp":1789475579,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["00570","BK1515","BK1606","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102382871","title":"中國中藥旗下子公司簽約山東益方改造項目，合同金額1060萬元及其他事項","url":"https://stock-news.laohu8.com/highlight/detail?id=1102382871","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102382871?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 20:31","pubTimestamp":1789475470,"startTime":"0","endTime":"0","summary":"中国中药发布公告称，其子公司精方药业已就山东益方改造项目达成承包协议。该项目合同总金额为人民币1060万元。值得注意的是，此次签约标志着公司在区域业务拓展上迈出了新的一步。除这一核心项目外，公告还披露了其他相关事项，进一步丰富了本次信息披露的内容维度。需关注的是，合同履行过程中仍存在原材料价格波动、施工进度不确定性等潜在风险因素。公司表示，将严格按照合同条款推进项目执行，确保按期保质完成各项建设任务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","00570","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667644950","title":"阿里健康(00241)授出合共767.25萬個受限制股份單位","url":"https://stock-news.laohu8.com/highlight/detail?id=2667644950","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667644950?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 19:50","pubTimestamp":1789473031,"startTime":"0","endTime":"0","summary":"智通财经APP讯，阿里健康(00241)发布公告，于2026年9月15日，公司根据2024年股份奖励计划得条款向16名承授人授出合共767.25万个受限制股份单位，但须待接纳后方可作实。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496427.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1142","BK1617","BK1615","BK1247","BK1589","HK0000165453.HKD","BK1502","BK1515","BK1610","BK1591","00241","BK1584","BK1571","BK1189","BK1501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667641986","title":"董事長兼總裁吳豫生增持同源康醫藥-B(02410.HK)40萬股 每股作價約2.82港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667641986","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667641986?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 19:07","pubTimestamp":1789470429,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","BK1574","02410","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667645058","title":"石藥集團(01093)：SYS 6010於中國獲國家藥監局納入突破性治療品種名單用於治療驅動基因陰性非鱗狀非小細胞肺癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2667645058","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667645058?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 18:04","pubTimestamp":1789466653,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团开发的SYS 6010近日获中华人民共和国国家药品监督管理局纳入突破性治疗品种名单，拟定适应症为既往接受过免疫治疗及含铂化疗治疗失败的复发或转移性驱动基因阴性非鳞状非小细胞肺癌。目前，评估该产品单药用于经标准治疗失败的驱动基因阴性局部晚期或转移性非鳞状非小细胞肺癌的随机、开放、多中心III期临床试验正在开展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496306.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"石药集团(01093)：SYS 6010于中国获国家药监局纳入突破性治疗品种名单用于治疗驱动基因阴性非鳞状非小细胞肺癌患者","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","HK0000165453.HKD","LU1226288170.HKD","LU1226287875.USD","LU1008478684.HKD","LU0314109678.HKD","LU0501845795.SGD","BK1521","LU1152091754.HKD","LU0880133367.SGD","LU0315179316.USD","IE00B543WZ88.USD","01093","LU0140636845.USD","LU2039709279.SGD","SG9999004220.SGD","LU1960683339.HKD","LU1993786604.SGD","IE00BZ08YS42.EUR","KURE","IE00B031HY20.USD","LU0067412154.USD","BK1191","IE0008369823.USD","LU0072913022.USD","IE00BZ08YR35.GBP","LU1328277881.USD","LU1813983027.USD","LU0326950275.SGD","LU1807302812.USD","LU1226287792.SGD","LU1226287529.USD","BK1515","IE0008368742.USD","LU1226288253.USD","IE00BZ08YT58.USD","LU1951186391.HKD","LU1152091168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667936645","title":"復星醫藥：9月15日回購130萬股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2667936645","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667936645?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 17:58","pubTimestamp":1789466293,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1593","02196","BK1191","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667664559","title":"勁方醫藥-B(02595)9月15日斥資129.56萬港元回購5萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667664559","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667664559?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 17:50","pubTimestamp":1789465841,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，于2026年9月15日，该公司斥资129.56万港元回购5万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02595","BK1515","159938","09939","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667645208","title":"復星醫藥(02196.HK)周二回購130萬股 涉2,207萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667645208","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667645208?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 17:49","pubTimestamp":1789465740,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布，于9月15日回购130万股，每股作价介乎16.89至17.1元，涉资约2,207.07万元。(da)(港股报价延迟最少十五分钟。沽空资料截至 2026-09-15 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180321105506149_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180321105506149_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544591/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544591/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0175","BK0183","BK0187","BK1191","BK0096","BK0188","600196","BK0196","02196","BK1515","BK1593","BK0012","BK0060","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667617050","title":"前任合作匆匆落幕後，彌可保推廣權易手國藥控股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667617050","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667617050?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 16:06","pubTimestamp":1789459577,"startTime":"0","endTime":"0","summary":"上任合作刚满一年，弥可保迎来新的推广方。9月14日晚间，卫材中国宣布与国药控股就弥可保针剂签署推广合作协议。值得注意的是，就在两个半月前，卫材中国与誉衡药业子公司天津博达的推广合作才刚刚终止。此前，卫材中国将该产品大陆地区独家推广权授予天津博达，合作仅维持一年多便匆匆宣告终止。彼时，誉衡药业曾在公告中透露，该合作产品对公司的收入贡献占整体收入的比例较低。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609153874698249.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609153874698249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1197","BK1500","01099","LU1115378108.SGD","LU0640798160.USD","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667612444","title":"阿里健康(00241)出現大手買入160萬股，成交價$2.915，涉資466.4萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2667612444","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667612444?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 15:20","pubTimestamp":1789456800,"startTime":"0","endTime":"0","summary":"[大手成交]阿里健康(00241)在下午03:20出现大手买入，成交量为160万，成交价为港币$2.915，涉资466.4万。至目前为止，股价跌3%，今日最高价为$3.03，而最低价为$2.91，总成交量为5.568千万股，总成交金额港币$1.641亿。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2609155258/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2609155258/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1142","BK1617","BK1615","BK1247","BK1589","HK0000165453.HKD","BK1502","BK1515","BK1610","BK1591","00241","BK1584","BK1571","BK1189","BK1501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667118556","title":"王老吉繼續「降温」","url":"https://stock-news.laohu8.com/highlight/detail?id=2667118556","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667118556?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 14:17","pubTimestamp":1789453022,"startTime":"0","endTime":"0","summary":"2025年，王老吉大健康公司营收小幅企稳，录得收入87.86亿元，净利润回升至12.02亿元，但始终未重现此前的增长势头。王老吉大健康公司的经营波动，直接牵动天然饮品板块的整体表现。这也反映出王老吉凉茶产品在终端动销走弱，传统单一凉茶大单品的增长红利已经消退，产品销售规模进入持续收缩阶段。在代言人布局上，王老吉去年签约张凌赫、世界杯期间签约哈兰德；今年8月在签约李昀锐代言“王者英雄能量电解质饮料”。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789001106238300805","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1191","BK1515","BK1197","BK1521","00874","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667359619","title":"鋰電池板塊走弱 寧德時代（03750）跌超4% 行業產能過剩壓力凸顯","url":"https://stock-news.laohu8.com/highlight/detail?id=2667359619","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667359619?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 13:45","pubTimestamp":1789451119,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股锂电池板块走弱，截至发稿，比亚迪电子（00285）跌1.97%，赣锋锂业（01772）跌2.46%，彩客新能源（01986）跌2.63%，天齐锂业（09696）跌3.65%，宁德时代（03750）跌4.92%。消息面上，近日，多家头部电池企业向经济观察报确认，今年下半年以来，各地基本已经停止受理新增动力电池、储能电池产能备案，新增动力、储能电池产能申报基本暂停。根据行业机构统计，今年储能电芯规划扩产已超800GWh，到年底建成产能约1.2至1.5TWh，规划总产能接近2TWh，远远超越了全球市场的真实需求。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/MGY1NDA5NTM4NDQ4Mw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MGY1NDA5NTM4NDQ4Mw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991666","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","300750","LU1008478684.HKD","LU1807302812.USD","LU0359201612.USD","LU0588546209.SGD","002466","BK1509","01986","BK1592","03750","BK1610","002460","BK1540","BK1129","BK1149","BK1607","00285","LU1152091168.USD","LU0067412154.USD","LU1993786604.SGD","BK1116","BK1190","LU1152091754.HKD","BK1167","SG9999006597.SGD","SG9999014674.SGD","BK1594","LU1960683339.HKD","LU1023057109.AUD","01772","LITP","LU0274383008.USD","SG9999003461.SGD","BK1504","LU0348766576.USD","BK1589","LU0307460666.USD","LU0359202008.SGD","BK1582","LU0880133367.SGD","BK1580","09696","LU0348767384.USD","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667619385","title":"港股異動 | 禮邦醫藥-B(09637)午後飆升逾17% AP308治療IgA腎病新藥臨床申請獲美國FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667619385","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667619385?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 13:36","pubTimestamp":1789450580,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，礼邦医药-B午后飙升逾17%。消息面上，礼邦医药近日宣布，AP308用于治疗IgA肾病的新药临床试验申请近日获美国食品药品监督管理局批准。公司计划于近期启动AP308的首次人体临床试验。AP308的IND获批标志着这一首创新药由临床前研究迈入临床开发阶段。公告指出，IgA肾病是全球最常见的原发性肾小球肾炎，2025年全球患者约950万人，其中中国约510万人，占全球过半。约60%中国患者于确诊后15年内进展至终末期肾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496084.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09637","BK1574","09939","159938","VXUS","BK1191","BK1515","BK4585","KCAI","LABU","BK1161","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667616045","title":"禮邦醫藥－Ｂ(09637)股價顯著上升14.696%，現價港幣$26.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2667616045","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667616045?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 13:30","pubTimestamp":1789450200,"startTime":"0","endTime":"0","summary":"[上升股]礼邦医药－Ｂ(09637) 股价在下午01:30比前收市价显著上升14.696%，现股价为港币$26.38。至目前为止，今日最高价为$26.38，而最低价为$22.78。总成交量为84.79万股，总成交金额为港币$2.12千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609151589/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609151589/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["159938","09637","BK1515","BK1161","BK1574","BK1191","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667616501","title":"渠道紅利見頂，主動投研掉隊  工銀瑞信的權益短板誰來補？","url":"https://stock-news.laohu8.com/highlight/detail?id=2667616501","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667616501?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 11:54","pubTimestamp":1789444440,"startTime":"0","endTime":"0","summary":"依托大股东工商银行遍布全国的庞大渠道网络，工银瑞信是国内银行系公募的代表性机构，总管理规模迈上 2.56 万亿元台阶，养老金业务也位居行业前列。当渠道红利逐渐见顶，产品业绩、人才体系、内控治理三重压力接踵而至，这家头部公募正迎来一场绕不开的考验。明星产品深度回撤风格漂移引争议根据工商银行年报披露的工银瑞信经营数据，2025 年全年，公司实现净利润 30.07 亿元，同比增长 42.5%；进入 2026 年上半年，公司增长势头进一步提速。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-15/doc-inirwsee3872484.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","BK1515","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667184356","title":"同源康醫藥－Ｂ(02410)股價大幅上升15.635%，現價港幣$3.55","url":"https://stock-news.laohu8.com/highlight/detail?id=2667184356","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667184356?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 10:44","pubTimestamp":1789440240,"startTime":"0","endTime":"0","summary":"[上升股]同源康医药－Ｂ(02410) 股价在上午10:43比前收市价大幅上升15.635%，现股价为港币$3.55。至目前为止，今日最高价为$3.55，而最低价为$3.175。总成交量为231.15万股，总成交金额为港币$775.694万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609151343/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609151343/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09939","02410","BK1574","BK1161","159938","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667690691","title":"港股異動 | 同源康醫藥-B(02410)漲逾10% 大股東增持提振市場信心 此前核心品種已順利獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2667690691","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667690691?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 10:02","pubTimestamp":1789437751,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B今早震荡走高，截至发稿，涨10.1%，报3.38港元，成交额389.48万港元。此外，今年8月底，同源康医药披露其核心品种顺利获批，公司自主研发的新一代EGFR-TKI创新药甲磺酸氘申艾替尼片已获得NMPA批准，在国内附条件上市，适应症为具有EGFR 19DEL或L858R置换突变，并伴有CNS转移的局部晚期或转移性非小细胞肺癌成人患者的一线治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496014.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1515","BK4585","BK4588","KCAI","BK1574","VXUS","09939","02410","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667694130","title":"勁方醫藥-B(02595.HK)：GFH375(口服KRAS G12D抑制劑)II期單藥治療 經治NSCLC優效數據登陸2026世界肺癌大會口頭報告","url":"https://stock-news.laohu8.com/highlight/detail?id=2667694130","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667694130?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 08:24","pubTimestamp":1789431858,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1515","09939","02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667134694","title":"勁方醫藥-B(02595)：GFH375(口服KRAS G12D抑制劑)II期單藥治療 經治NSCLC優效數據登陸2026世界肺癌大會口頭報告","url":"https://stock-news.laohu8.com/highlight/detail?id=2667134694","media":"智通财经","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667134694?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 08:24","pubTimestamp":1789431858,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B 发布公告，GFH375单药治疗经治KRASG12D突变型非小细胞肺癌的II期试验更新数据，于当地时间9月14日登陆今年在首尔举行的世界肺癌大会口头报告。截至2026年9月4日，共有75名KRASG12D突变型NSCLC患者接受600mgQD口服GFH375治疗，其中98.7%的患者存在远处转移，包括骨转移、脑转移(16%)、肝转移等。截至2026年6月17日，75名患者接受GFH375单药治疗后显示安全性/耐受性可控。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495970.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","02595","09939","159938","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667670666","title":"董事長兼總裁吳豫生增持同源康醫藥-B(02410)17萬股 每股作價約2.7港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667670666","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667670666?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:07","pubTimestamp":1789384024,"startTime":"0","endTime":"0","summary":"9月11日，董事长兼总裁吴豫生增持同源康医药-B(02410)17万股，每股作价2.7036港元，总金额约为45.96万港元。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260914/20260914190726_24966.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260914/20260914190726_24966.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495790.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["09939","159938","EWH","BK1574","BK1161","BK1515","02410"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":1,"totalSize":205,"code":"91000000","status":"200"}]}}